Afyx Therapeutics A/S: Financial statements 2019
CVR: 38793594
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -1,134,301 and a net result of DKK -1,569,660. Equity in the 2019 report amounted to DKK 1,032,124. The solvency ratio was 45.4%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,134,301
- Profit/Loss
- DKK -1,569,660
- Equity
- DKK 1,032,124
- Total Assets
- DKK 2,272,600
- Employees
- 1
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Afyx Therapeutics A/S has published its interim report for the period July 12, 2017 to December 31, 2018.
About Afyx Therapeutics A/S
Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.
